Trevi Therapeutics
Trevi Therapeutics Logo
About Trevi Therapeutics
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio, an oral extended-release formulation of nalbuphine, for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), pruritus, and prurigo nodularis. Haduvio targets the central and peripheral nervous systems and is being evaluated in multiple clinical trials. The company is headquartered in New Haven, Connecticut, and was founded in 2011.
Address
195 Church Street, 16th Floor
New Haven, 06510
United States
Year founded
2011
Number of employees
0-100
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
